GlassScriptPhysician profile
Danielle K Reimer
NPI 1215432794
$2,703.90
in general payments reported to CMS, 2019-2025
20 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $214 · 2021: $735 · 2022: $429 · 2023: $227 · 2024: $457 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.71 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $532.34 | 2020-2022 | |
| Janssen Biotech, INC. | $347.05 | 2021-2025 | Tremfya |
| Abbvie INC. | $346.61 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $305.82 | 2019-2025 | Libtayo, Dupixent |
| Arcutis Biotherapeutics, INC. | $241.29 | 2024-2025 | Zoryve |
| Genzyme Corporation | $164.00 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $146.07 | 2023-2025 | Odomzo, Blu-U, Winlevi |
| Lilly USA, LLC | $138.58 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Galderma Laboratories, L.P. | $124.71 | 2021 | |
| Almirall LLC | $70.44 | 2023-2025 | Klisyri, Seysara |
| Pfizer INC. | $50.62 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $44.60 | 2022-2024 | Sotyktu |
| Amgen INC. | $41.15 | 2023-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.79 | 2024 | Spevigo |
| Leo Pharma INC. | $26.98 | 2024 | Adbry |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.70 | 2025 | |
| Verrica Pharmaceuticals INC. | $19.14 | 2023 | Ycanth |
| Botanix Sb INC | $18.86 | 2025 | Sofdra |
| Journey Medical Corporation | $17.85 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.30 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Reimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.